文献速递骨质疏松与代谢性骨病

阿巴洛肽降低绝经后骨质疏松症女性非椎体与椎体骨折风险:一项网络Meta分析

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
PubMed 文献 · Osteoporos Int · 2019-04-06

该网络Meta分析评估阿巴洛肽对比其他治疗方案降低绝经后骨质疏松症女性骨折风险的相对疗效。共筛选4978篇文献,纳入22项随机对照试验,结果显示阿巴洛肽在椎体、非椎体和腕部骨折网络中相对安慰剂的疗效均最优。作者结论为阿巴洛肽可降低椎体、非椎体和腕部骨折的相对风险。

要点

  • 阿巴洛肽在椎体骨折网络中对安慰剂的RR=0.13(95%CrI 0.04-0.34)。
  • 非椎体骨折网络RR=0.50(95%CrI 0.28-0.85),腕部骨折网络RR=0.39(95%CrI 0.15-0.90)。
  • 治疗排名显示阿巴洛肽预防骨折的估计概率最高:椎体79%、非椎体70%、腕部53%。

核心结论

  • 该网络Meta分析表明,阿巴洛肽可降低绝经后骨质疏松症女性(无论既往有无骨折)椎体、非椎体和腕部骨折相对安慰剂的相对风险,且优于其他治疗选择。

研究设计与样本

  • 检索PubMed、Embase和Cochrane对照试验中心注册库,纳入2017年12月20日前发表的、包含符合初级或次级骨折预防干预条件的绝经后骨质疏松症女性的随机对照试验。
  • 共筛选4978篇文献,最终纳入22项研究进行分析。
  • 按骨折部位(椎体、非椎体、腕部)分别进行网络Meta分析,以相对安慰剂的骨折相对风险为主要临床终点,采用固定效应和随机效应方法。

主要发现

  • 与其他治疗相比,阿巴洛肽在椎体骨折网络中对安慰剂的疗效最大(RR=0.13;95%可信区间0.04-0.34)。
  • 在非椎体骨折网络中RR=0.50(95%可信区间0.28-0.85),在腕部骨折网络中RR=0.39(95%可信区间0.15-0.90)。
  • 治疗排名显示阿巴洛肽在各网络中预防骨折的估计概率最高:椎体79%、非椎体70%、腕部53%。
  • 各网络与直接试验证据及直接配对比较显示良好的一致性。

局限性

  • 局限性包括未考虑不良事件和药物成本。
  • 普遍性仅限于网络Meta分析纳入的试验人群和终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This network meta-analysis assessed the efficacy of abaloparatide versus other treatment options to reduce the risk of fractures in women with postmenopausal osteoporosis. The analysis indicates that abaloparatide reduces the risk of fractures in women with postmenopausal osteoporosis versus placebo and compared with other treatment options. INTRODUCTION: This network meta-analysis (NMA) assessed the relative efficacy of abaloparatide versus other treatments to reduce the risk of fractures in women with postmenopausal osteoporosis (PMO). METHODS: PubMed®, Embase®, and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials published before December 20, 2017, that included women with PMO who were eligible to receive interventions for primary or secondary fracture prevention. The NMA was conducted by fracture site (vertebral [VF], nonvertebral [NVF], and wrist), with the relative risk (RR) of fracture versus placebo the main clinical endpoint. The NMA used fixed-effects and random-effects approaches. RESULTS: A total of 4978 articles were screened, of which 22 were included in the analysis. Compared with other treatments, abaloparatide demonstrated the greatest treatment effect relative to placebo in the VF network (RR = 0.13; 95% credible interval [CrI] 0.04-0.34), the NVF network (RR = 0.50; 95% CrI 0.28-0.85), and the wrist fracture network (RR = 0.39; CrI 0.15-0.90). Treatment ranking showed that abaloparatide had the highest estimated probability of preventing fractures in each of the networks (79% for VF, 70% for NVF, and 53% for wrist fracture) compared with other treatments. Individual networks demonstrated a good level of agreement with direct trial evidence and direct pair-wise comparisons. CONCLUSIONS: This NMA indicates that abaloparatide reduces the RR of VF, NVF, and wrist fracture in women with PMO with or without prior fracture versus placebo, compared with other treatment options. Limitations include that adverse events and drug costs were not considered, and that generalizability is limited to the trial populations and endpoints included in the NMA.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Reginster J-, Bianic F, Campbell R, et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019. PMID: 30953114. doi:10.1007/s00198-019-04947-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。